News und Analysen
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron BA.1-Adapted Bivalent COVID-19 Vaccine Booster in European Union
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced a 30-µg booster dose of their Omicron BA.1 Bivalent COVID-19 Vaccine (COMIRNATY® Original/Omicron BA.1 15/15 µg) has been
Agilent Collaborates with METTLER TOLEDO to Reduce Errors in Sample Preparation Workflows for Better Chromatographic Results
Agilent Technologies Inc. (NYSE: A) today announced that it is collaborating with METTLER TOLEDO to address one of the biggest concerns in any laboratory—error-prone sample preparation. This
DexCom Promotes Jake Leach to Chief Operating Officer
DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today the promotion of Jake Leach to the role of chief operating
Pfizer and BioNTech Granted FDA Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster for Ages 12 Years and Older
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the U.S. Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) of a 30-µg booster dose of the
Texas A&M University Mays Business School and Humana Launch Sixth Annual Healthcare Analytics Case Competition
Mays Business School at Texas A&M University and leading health and well-being company Humana Inc. have announced the details of the 2022 Humana-Mays Healthcare Analytics Case Competition, which
Pfizer and BioNTech Complete Submission to European Medicines Agency for Omicron BA.4/BA.5 Adapted Bivalent Vaccine
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have completed a submission to the European Medicines Agency (EMA) for a booster dose of an Omicron BA.4/BA.5-adapted
Pfizer Announces Positive Top-Line Data from Phase 3 Trial of Older Adults for its Bivalent Respiratory Syncytial Virus (RSV) Vaccine Candidate
Pfizer Inc. (NYSE: PFE) today announced positive top-line data from the Phase 3 clinical trial (NCT05035212) RENOIR (RSV vaccine Efficacy study iN Older adults Immunized against RSV disease)
Pfizer and BioNTech Announce Updated COVID-19 Vaccine Data Supporting Efficacy in Children 6 Months through 4 Years of Age
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced updated efficacy results from a Phase 2/3 trial evaluating a three 3-µg dose series of the Pfizer-BioNTech COVID-19 Vaccine in
Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have completed a submission to the U.S. Food and Drug Administration (FDA) requesting Emergency Use Authorization (EUA)
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with Mikael Dolsten, Chief Scientific Officer, President, Worldwide Research
QuidelOrtho Announces $300 Million Share Repurchase Authorization
QuidelOrtho Corporation (NASDAQ: QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion
Agilent Reports Third-Quarter Fiscal Year 2022 Financial Results
Agilent Technologies Inc. (NYSE: A) today reported revenue of $1.72 billion for the third quarter ended July 31, 2022, an increase of 8% compared to the third quarter of 2021 and up 13% on a core(1
Pfizer Announces Positive Top-Line Results from Phase 3 Study of 20-Valent Pneumococcal Conjugate Vaccine in Infants
Pfizer Inc. (NYSE:PFE) today announced positive top-line results from its pivotal U.S. Phase 3 study (NCT04382326) in infants evaluating its 20-valent pneumococcal conjugate vaccine candidate
Pfizer and Valneva Initiate Phase 3 Study of Lyme Disease Vaccine Candidate VLA15
Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced the initiation of a Phase 3 clinical study, Vaccine Against Lyme for Outdoor Recreationists (VALOR)
Pfizer to Acquire Global Blood Therapeutics for $5.4 Billion to Enhance Presence in Rare Hematology
Pfizer Inc. (NYSE: PFE) and Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced the companies have entered into a definitive agreement under which Pfizer will acquire GBT, a
QuidelOrtho Reports Second Quarter 2022 Financial Results
QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a leading in vitro diagnostics company, today announced financial results for the second quarter ended July 3, 2022.
The
Dexcom Announces Upcoming Conference Presentation
DexCom, Inc. (NASDAQ:DXCM) today announced that Jereme Sylvain, Executive Vice President and Chief Financial Officer, will present an update on the company at the Canaccord Genuity 42nd Annual
Humana Foundation Donates $500,000 to Support Recovery in Wake of Devastating Flooding
The Humana Foundation, the philanthropic arm of Humana Inc. (NYSE: HUM) for the past 40 years, is donating $500,000 towards relief and recovery efforts for those impacted by torrential rains and
Agilent Acquires Polymer Standards Service, Broadening Offerings for GPC/SEC Polymer Analysis
Agilent Technologies Inc. (NYSE: A) today announced it has acquired Polymer Standards Service GmbH (PSS), a provider of solutions in the field of polymer characterization. PSS specializes in
Agilent Announces Thought Leader Award to Gerhardt Attard at University College London (UCL)
Agilent Technologies Inc. (NYSE: A) today announced that Professor Gerhardt Attard has been selected to receive a prestigious Agilent Thought Leader Award. Prof Attard is a John Black Charitable
Dexcom ONE real-time Continuous Glucose Monitoring (rt-CGM) System available on prescription in the UK, improving access to rt-CGM for people with diabetes
DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, and NHS England today announced the availability of the easy to use Dexcom ONE
Humana ranked No. 1 among health insurers for Customer Experience
For two years in a row, Humana ranked No. 1 among health insurers for customer experience (CX) quality in Forrester’s proprietary 2022 U.S. Customer Experience Benchmark survey. The ranking was
Dexcom Reports Second Quarter 2022 Financial Results
DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended June 30, 2022.
Second Quarter 2022 Financial Highlights:
-
Revenue grew 17% versus the same
PFIZER REPORTS SECOND-QUARTER 2022 RESULTS
Pfizer Inc. (NYSE: PFE) reported strong financial results for second-quarter 2022 and updated certain components of 2022 financial guidance(4). Pfizer reaffirmed its previous 2022 revenue guidance
Agilent 2022 Early Career Professor Award Presented to Stefanos Nikolaidis
Agilent Technologies Inc. (NYSE: A) announced today that Stefanos Nikolaidis Ph.D. has received the Agilent 2022 Early Career Professor Award. Dr. Stefanos Nikolaidis is an Assistant Professor of